Cost-Effectiveness of Bariatric Surgery Compared With Nonsurgical Treatment in People With Obesity and Comorbidity in Colombia

Gil-Rojas, Yaneth; Ceballos-Garzón, Andrés; Lasalvia, Pieralessandro; Hernández, Fabián; Castañeda‐Cardona, Camilo; Rosselli, Diego

doi:10.1016/j.vhri.2019.01.010

Cited by 8 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of studies are described in Tables 1 and S3 . As for country income level, 24 [ 25 – 35 , 37 – 43 , 45 – 50 ] (85.7%) and 4 [ 36 , 44 , 51 , 52 ] (14.3%) studies were conducted in HICs and UMICs, respectively. From these, 20 (71.4%) were conducted in mixed obesity group (i.e., with/without diabetes), whereas 8 [ 45 – 52 ] (28.6%) studies were conducted in obesity with diabetes group.…”

Section: Resultsmentioning

confidence: 99%

“…One study [ 29 ] adopted societal perspective and two studies [ 27 , 49 ] did not clearly mention the perspective. Lifetime, 10-year, and less than 10-year horizons were respectively used in 18 [ 25 – 27 , 29 , 30 , 32 – 35 , 37 – 43 , 48 , 49 ], 10 [ 28 , 30 , 31 , 34 , 35 , 39 , 41 – 44 ], and 5 studies [ 27 , 30 , 45 , 46 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

“…Of the four studies from UMICs [ 36 , 44 , 51 , 52 ], three studies [ 36 , 44 , 51 ] with five comparisons were conducted in mixed obesity group, while four comparisons [ 36 , 44 , 51 , 52 ] were conducted in obesity with diabetes group [ 36 , 44 , 51 , 52 ] (see Table S6 ). Time horizon varied across studies, i.e., 5 years [ 51 ], 10 years [ 44 ], 20 years [ 36 ], and 50 years [ 52 ]. All studies adopted a payer perspective [ 36 , 44 , 51 , 52 ].…”

Section: Resultsmentioning

confidence: 99%

“…Four studies [ 27 , 31 , 45 , 46 ] had unclear risk of wrong model bias. Three studies [ 45 , 46 , 51 ] adopted short-term time-horizon of 5 years, four studies [ 28 , 31 , 36 , 44 ] used mid-term period of 10 and 20 years, and 18 studies [ 25 – 27 , 29 , 30 , 32 – 35 , 37 – 43 , 48 , 49 ] adopted lifetime horizon. Partial biases related to treatment effect, intermittent data collection, and quality of life weight occurred in almost all studies.…”

Section: Resultsmentioning

confidence: 99%

“…Data on long-term treatment effect of bariatric surgery and utility per unit of BMI change were limited. Moreover, half of the studies [ 25 – 29 , 31 , 37 , 38 , 40 , 44 – 46 , 48 , 49 , 51 , 52 ] were subjected to bias related to internal consistency.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

et al. 2021

View full text Add to dashboard Cite

This systematic review aimed to comprehensively synthesize cost-effectiveness evidences of bariatric surgery by pooling incremental net monetary benefits (INB). Twenty-eight full economic evaluation studies comparing bariatric surgery with usual care were identified from five databases. In high-income countries (HICs), bariatric surgery was cost-effective among mixed obesity group (i.e., obesity with/without diabetes) over a 10-year time horizon (pooled INB = $53,063.69; 95% CI $42,647.96, $63,479.43) and lifetime horizon (pooled INB = $101,897.96; 95% CI $79,390.93, $124,404.99). All studies conducted among obese with diabetes reported that bariatric surgery was cost-effective. Also, the pooled INB for obesity with diabetes group over lifetime horizon in HICs was $80,826.28 (95% CI $32,500.75, $129,151.81). Nevertheless, no evidence is available in low- and middle-income countries. Graphical abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

et al. 2021

View full text Add to dashboard Cite

show abstract

Can responsive deep brain stimulation be a cost‐effective treatment for severe obesity?

Mahajan

Ojukwu

Azagury

et al. 2022

Obesity

View full text Add to dashboard Cite

The global obesity epidemic has an undeniably high economic burden, with its associated annual medical spending in the US alone totaling $150 billion in 2010 (1). The financial cost per patient with obesity is similarly high in other nations, including in low-and middle-income countries (2). At the turn of the 21st century, obesity accounted for up to 3% of a country's total health expenditures (3). In the years following, both the global prevalence of obesity and disease burden related to high BMI have steadily increased within every sociodemographic quintile (4). Most recently, the societal safety measures imposed during the COVID-19 pandemic will likely have long-term negative effects on the obesity epidemic (5).Notably, the relationship between BMI and health care costs is nonlinear, i.e., health care costs rise exponentially for the few individuals with the most severe obesity (6). Indeed, the 10% of the population of individuals with overweight/obesity with the highest BMI account for more than 60% of the global disease burden related to obesity (7). Therefore, it becomes critical to identify, examine, and provide cost-effective treatments for individuals with severe obesity. Bariatric surgery is an established treatment for severe obesity, shown to be cost-effective in the US (8), Europe (9), Asia (10), South America (11), and Australia (12). However, in patients with severe

show abstract

Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations

et al. 2022

View full text Add to dashboard Cite

Aim To systematically identify and appraise the international literature on the cost-effectiveness of metabolic surgery for the treatment of comorbid type 2 diabetes (T2D) and obesity. Methods A systematic search was conducted in electronic databases and grey literature sources up to 20 January 2021. Economic evaluations in a T2D population or a subpopulation with T2D were eligible for inclusion. Screening, data extraction, critical appraisal of methodological quality (Consensus Health Economic Criteria list) and assessment of transferability (International Society for Pharmacoeconomics and Outcomes Research questionnaire) were undertaken in duplicate. The incremental cost-effectiveness ratio (ICER) was the main outcome. Costs were reported in 2020 Irish Euro. Cost-effectiveness was interpreted using willingness-to-pay (WTP) thresholds of €20,000 and €45,000/quality-adjusted life year (QALY). Due to heterogeneity arising from various sources, a narrative synthesis was undertaken. Results Thirty studies across seventeen jurisdictions met the inclusion criteria; 16 specifically in a T2D population and 14 in a subpopulation with T2D. Overall, metabolic surgery was found to be cost-effective or cost-saving. Where undertaken, the results were robust to sensitivity and scenario analyses. Of the 30 studies included, 15 were considered high quality. Identified limitations included limited long-term follow-up data and uncertainty regarding the utility associated with T2D remission. Conclusion Published high-quality studies suggest metabolic surgery is a cost-effective or cost-saving intervention. As the prevalence of obesity and obesity-related diseases increases worldwide, significant investment and careful consideration of the resource requirements needed for metabolic surgery programmes will be necessary to ensure that service provision is adequate to meet demand.

show abstract

Cost-Effectiveness of Bariatric Surgery Compared With Nonsurgical Treatment in People With Obesity and Comorbidity in Colombia

Cited by 8 publications

References 23 publications

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

Can responsive deep brain stimulation be a cost‐effective treatment for severe obesity?

Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations

Contact Info

Product

Resources

About